Department of Cardiac Surgery, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles, California.
Department of Cardiology, Cedars Sinai Medical Center, Smidt Heart Institute, Los Angeles, California.
J Heart Lung Transplant. 2023 Aug;42(8):1045-1053. doi: 10.1016/j.healun.2023.04.010. Epub 2023 Apr 23.
Given ongoing donor shortages, appropriate patient selection for dual-organ transplantation is critical. We evaluated outcomes of heart retransplant with simultaneous kidney transplant (HRT-KT) vs isolated heart retransplant (HRT) across varying levels of renal dysfunction.
The United Network for Organ Sharing database identified 1189 adult patients undergoing heart retransplantation between 2005 and 2020. Recipients undergoing HRT-KT (n = 251) were compared to those undergoing HRT (n = 938). The primary outcome was 5-year survival; subgroup analyses and multivariable adjustment were performed utilizing the following 3 estimated glomerular filtration (eGFR) groups: <30 ml/min/1.73m, 30-45 ml/min/1.73m, and >45 ml/min/1.73m.
HRT-KT recipients were older and had longer waitlist times, longer inter-transplant periods, and lower eGFR levels. HRT-KT recipients were less likely to require pretransplant ventilator (1.2% vs 9.0%, p < 0.001) or ECMO (2.0% vs 8.3%, p < 0.001) support but were more likely to have severe functional limitation (63.4% vs 52.6%, p = 0.001). After retransplantation, HRT-KT recipients had less treated acute rejection (5.2% vs 9.3%, p = 0.02) and more dialysis requirement (29.1% vs 20.2%, p < 0.001) before discharge. Survival at 5-years was 69.1% after HRT and 80.5% after HRT-KT (p < 0.001). After adjustment, HRT-KT was associated with improved 5-year survival among recipients with eGFR <30 ml/min/1.73m (HR:0.42, 95% CI: 0.26-0.67) and 30 to 45 ml/min/1.73m (HR:0.29, 95% CI 0.13-0.65), but not among those with eGFR>45 ml/min/1.73sm (HR 0.68, 95% CI 0.30-1.54).
Simultaneous kidney transplantation is associated with improved survival following heart retransplantation in patients with eGFR <45 ml/min/1.73m and should be strongly considered to optimize organ allocation stewardship.
鉴于供体短缺,对双器官移植进行适当的患者选择至关重要。我们评估了不同肾功能水平下心脏再移植同时进行肾脏移植(HRT-KT)与单独心脏再移植(HRT)的结果。
美国器官共享网络数据库确定了 2005 年至 2020 年间进行心脏再移植的 1189 名成年患者。将接受 HRT-KT(n=251)的患者与接受 HRT(n=938)的患者进行比较。主要结果是 5 年生存率;利用以下 3 个估计肾小球滤过率(eGFR)组进行亚组分析和多变量调整:<30ml/min/1.73m、30-45ml/min/1.73m 和>45ml/min/1.73m。
HRT-KT 受者年龄较大,等待时间较长,移植间隔较长,eGFR 水平较低。HRT-KT 受者需要接受术前呼吸机(1.2%比 9.0%,p<0.001)或 ECMO(2.0%比 8.3%,p<0.001)支持的可能性较小,但更有可能存在严重的功能受限(63.4%比 52.6%,p=0.001)。在再移植后,HRT-KT 受者的急性排斥反应发生率较低(5.2%比 9.3%,p=0.02),透析需求较高(29.1%比 20.2%,p<0.001)。HRT 后 5 年生存率为 69.1%,HRT-KT 后为 80.5%(p<0.001)。调整后,在 eGFR<30ml/min/1.73m(HR:0.42,95%CI:0.26-0.67)和 30-45ml/min/1.73m(HR:0.29,95%CI 0.13-0.65)的患者中,HRT-KT 与 5 年生存率的提高相关,但在 eGFR>45ml/min/1.73sm 的患者中(HR 0.68,95%CI 0.30-1.54),HRT-KT 与 5 年生存率的提高无关。
在 eGFR<45ml/min/1.73m 的患者中,心脏再移植同时进行肾脏移植与心脏再移植后生存率的提高相关,应强烈考虑以优化器官分配管理。